{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:15:40Z","timestamp":1790957740719,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2283,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1111\/j.1365-2133.2008.08962.x","type":"journal-article","created":{"date-parts":[[2008,12,15]],"date-time":"2008-12-15T11:00:05Z","timestamp":1229338805000},"page":"1264-1272","source":"Crossref","is-referenced-by-count":64,"title":["Economic evaluation of systemic therapies for moderate to severe psoriasis"],"prefix":"10.1093","volume":"160","author":[{"given":"S.","family":"Sizto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bansback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Willian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Anis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMoa021359","article-title":"Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis","volume":"349","author":"Heydendael","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB2","volume-title":"About Psoriasis: Statistics","author":"National Psoriasis Foundation","year":"2008"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.sder.2005.01.004","article-title":"The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care","volume":"24","author":"Stein","year":"2005","journal-title":"Semin Cutan Med Surg"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jdermsci.2005.01.011","article-title":"Update on the mechanisms and efficacy of biological therapies for psoriasis","volume":"38","author":"Koo","year":"2005","journal-title":"J Dermatol Sci"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14656566.7.2.157","article-title":"Cost-effectiveness of moderate-to-severe psoriasis treatment","volume":"7","author":"Miller","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB6","volume-title":"Final Appraisal Determination: Efalizumab and Etanercept for the Treatment of Adults with Psoriasis","author":"National Institute for Health and Clinical Excellence","year":"2005"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2004.06070.x","article-title":"Biological therapies in the systemic management of psoriasis: international consensus conference","volume":"151","author":"Sterry","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2005.06893.x","article-title":"British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005","volume":"153","author":"Smith","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB9","first-page":"1","article-title":"Etanercept and efalizumab for the treatment of psoriasis: a systematic review","volume":"10","author":"Woolacott","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1017\/S0266462300008461","article-title":"Utilities and quality-adjusted life years","volume":"5","author":"Torrance","year":"1989","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis: oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB12","volume-title":"Summary of Product Characteristics","author":"Electronic Medicines Compendium"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB13","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study","volume":"4","author":"Shikiar","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1067\/mjd.2002.122755","article-title":"Quantifying the harmful effect of psoriasis on health-related quality of life","volume":"47","author":"Weiss","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB17","volume-title":"British National Formulary 53","author":"British Medical Association","year":"2007"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB18","volume-title":"NHS Reference Costs 2003 and National Tariff 2004 (Payment by Results Core Tools 2004)","author":"Department of Health","year":"2004"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1365-2133.1999.02712.x","article-title":"The value of in-patient dermatology: a survey of in-patients in Scotland and northern England","volume":"140","author":"Munro","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB20","volume-title":"Conference of the European Academy of Dermatology and Venereology","author":"Sato","year":"2006"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1610-0387.2007.06240.x","article-title":"Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study","volume":"5","author":"Schoffski","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000093848","article-title":"Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis","volume":"213","author":"Schmitt","year":"2006","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/09546630500482886","article-title":"The negative impact of psoriasis on the workplace","volume":"17","author":"Pearce","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB24","volume-title":"Guide to the Methods of Technology Appraisal","author":"National Institute for Clinical Excellence (NICE)","year":"2004"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1610-0387.2005.05729.x","article-title":"Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany","volume":"3","author":"Berger","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy","volume":"17","author":"Gordon","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB29","first-page":"238","article-title":"A method for identifying optimum treatment sequences in chronic diseases","volume":"25","author":"Hawkins","year":"2005","journal-title":"Med Decis Making"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/09546630600920041","article-title":"Adverse events from systemic therapies for psoriasis are common in clinical practice","volume":"17","author":"Pearce","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB31","article-title":"Previous biological therapies influence the rate of response to etanercept in chronic plaque psoriasis","volume":"154","author":"Costanzo","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0190-9622(97)70172-5","article-title":"The economic impact of psoriasis increases with psoriasis severity","volume":"37","author":"Feldman","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1067\/S0190-9622(03)00858-2","article-title":"PUVA Follow-up Study. Inpatient hospital care for psoriasis: a vanishing practice in the United States","volume":"49","author":"Stern","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2133.2007.08338.x","article-title":"Inpatient management of psoriasis. A multicentre service review to establish national admission standards","volume":"158","author":"Woods","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB36","volume-title":"winBUGS","author":"MRC Biostatistics Unit"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2133.1999.02977.x","article-title":"Intermittent short courses of cyclosporin (Neoral\u00ae) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES study group","volume":"141","author":"Ho","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/rheumatology\/keh514","article-title":"Brition Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG). Guideline for anti-TNF-alpha therapy in psoriatic arthritis","volume":"44","author":"Kyle","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB39","volume-title":"Unit Costs of Health and Social Care 2006","author":"Personal Social Services Research Unit"},{"key":"10.1111\/j.1365-2133.2008.08962.x-BIB40","volume-title":"2006 Annual Survey of Hours and Earnings","author":"National Statistics"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2008.08962.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2008.08962.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:43:41Z","timestamp":1676382221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/160\/6\/1264\/6641919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08962.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}